A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Summary

The primary hypothesis of the study is single doses of MK-8351 will reduce the baseline early asthmatic response (EAR) as assessed by area under the curve from 0-3 hours (AUC0-3hr) of forced expiratory volume (FEV1) when compared to placebo.

Timeline

Start

2013-09

Primary completion

2014-04

Completion

2014-04

Drugs

Indications